Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
8(26%)
Results Posted
0%(0 trials)
Terminated
1(3%)

Phase Distribution

Ph early_phase_1
1
3%
Ph phase_1
1
3%
Ph not_applicable
6
19%
Ph phase_2
1
3%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
1(11.1%)
N/ANon-phased studies
6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

8

trials recruiting

Total Trials

31

all time

Status Distribution
Active(9)
Completed(8)
Terminated(3)
Other(11)

Detailed Status

unknown11
Completed8
Recruiting6
Active, not recruiting2
Withdrawn2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
8
Success Rate
88.9%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (11.1%)
Phase 11 (11.1%)
Phase 21 (11.1%)
N/A6 (66.7%)

Trials by Status

unknown1135%
not_yet_recruiting13%
active_not_recruiting26%
completed826%
terminated13%
recruiting619%
withdrawn26%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT06996561Phase 2

Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management

Recruiting
NCT02780128Phase 1

Next Generation Personalized Neuroblastoma Therapy

Terminated
NCT05032092Not Applicable

Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer

Active Not Recruiting
NCT05046444

Solving Riddles Through Sequencing

Recruiting
NCT02118818

RhEumatiC Heart diseAse Genetics

Completed
NCT05382585

Newer Therapeutic Targets in Head and Neck Cancers

Recruiting
NCT05404347

NGS in Gallbladder Cancer and Response to Treatment

Recruiting
NCT05013437Early Phase 1

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

Withdrawn
NCT06307405

The Value of mNGS in Diagnosis of Pulmonary Infection

Not Yet Recruiting
NCT05183906

Evaluation of Next-Generation Sequencing-based Metabarcoding Versus Culturing for Microbiological Assessment in Infectious Keratitis

Recruiting
NCT05048381

miRNA in Sweat, a Novel Digital Biomarker for Detection of Active Tuberculosis (TB)

Withdrawn
NCT05783973

Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract Carcinomas

Unknown
NCT05811169

Quest for Tumour Evolution of Non-small Cell Lung Cancer

Active Not Recruiting
NCT03820531Not Applicable

DNA-mutation Analysis in Cyst Fluid of Suspected Intraductal Papillary Mucinous Neoplasia of the Pancreas

Completed
NCT03066310

Urine-DNA Biomarkers in Detecting Bladder Cancer

Completed
NCT04689750

Donor CHIP and Allogeneic HSCT Outcome

Recruiting
NCT04122833

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

Unknown
NCT04110769Not Applicable

Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer

Unknown
NCT04313231

Sterile Inflammation and Molecular Aberrations in MDS

Unknown
NCT05254145

Joint Microbiome Study for the Knee

Unknown

Drug Details

Intervention Type
GENETIC
Total Trials
31